BIOMAT Database Logo BIOMAT Database Logo

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. 1997

C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Service d'Hématologie Clinique, Hôpital Henri Mondor, Créteil, France.

We conducted a randomized multicenter study to compare the efficacy and safety of two antibiotic regimens (cefepime [2 g b.i.d.] plus amikacin or ceftazidime [2 g t.i.d.] plus amikacin) as first-line therapy for fever in patients with hematologic malignancies and neutropenia. A total of 353 patients were randomized according to a 2:1 (cefepime:ceftazidime) ratio. Two hundred-twelve patients in the cefepime group and 107 in the ceftazidime group (90% of all patients) were evaluable for efficacy. The polymorphonuclear neutrophil count was < 100/mm3 on enrollment for 70% of the patients. The mean duration of neutropenia was 26 days. The efficacy in both study arms was comparable, although a trend in favor of cefepime was seen in terms of therapeutic success (response rate, 27% vs. 21% for the ceftazidime group). The overall response rate after glycopeptides were added to the regimens was 60% for the cefepime group and 51% for the ceftazidime group; the bacterial eradication rates were 81% vs. 76%, respectively, and the rates of new bacterial infections were 14% vs. 18%, respectively. We conclude that the combination cefepime/amikacin is at least as effective as the reference regimen of ceftazidime/amikacin in this setting.

UI MeSH Term Description Entries
D008297 Male Males
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D005767 Gastrointestinal Diseases Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Cholera Infantum,Gastrointestinal Disorders,Functional Gastrointestinal Disorders,Gastrointestinal Disorders, Functional,Disease, Gastrointestinal,Diseases, Gastrointestinal,Functional Gastrointestinal Disorder,Gastrointestinal Disease,Gastrointestinal Disorder,Gastrointestinal Disorder, Functional
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria

Related Publications

C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
January 1999, Chemotherapy,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Ceftazidime and amikacin as empirical treatment of febrile episodes in neutropenic patients.
May 1994, The Journal of infection,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
January 1991, Chemotherapy,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies.
December 2007, Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
February 1998, Annals of hematology,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
January 1997, Haematologica,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients.
March 2000, Annals of hematology,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Ceftazidime sodium carbonate versus ceftazidime arginine as empirical monotherapy in febrile neutropenic patients.
April 1988, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
January 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
C Cordonnier, and R Herbrecht, and J L Pico, and M Gardembas, and A Delmer, and M Delain, and P Moreau, and S Ladeb, and V Nalet, and C Rollin, and J J Gres
Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia.
July 1992, The Journal of infection,
Copied contents to your clipboard!